Evidence map›Paper›PMID 40217262›Full record

ArticleBMC psychiatry2025

Mentalization-based treatment versus bona fide treatment for patients with borderline personality disorder in Germany (MAGNET): study protocol of a prospective, multi-centre randomized controlled trial.

Sophie Hauschild, Svenja Taubner, Thorsten Vidalón Blachowiak, Ulrike Dinger, Harald Gündel, Sabine C Herpertz, Jörg Rademacher, Bernhard Strauss, Timo Storck, Ralitsa Vassileva and 6 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06018272 (Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06018272 narecruitingnot on this map

Mentalisierungsbasierte Therapie Versus Bona-fide-Therapie für Patient:Innen Mit Borderline-Persönlichkeitsstörung in Deutschland (MaGnet): Eine Prospektive, Multizentrische Randomisiert-kontrollierte Studie Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany (MAGNET): a Prospective, Multi-centre Randomized Controlled Trial

TypeinterventionalSponsorHeidelberg UniversityRan2024 to 2028Enrolled304ConditionsBorderline Personality DisorderArmsMentalization-Based Treatment (MBT), Bona-Fide Treatment in Germany (BFT)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sophie HauschildInstitute for Psychosocial Prevention, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany. sophie.hauschild@med.uni-heidelberg.de.
Svenja TaubnerInstitute for Psychosocial Prevention, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.
Thorsten Vidalón BlachowiakInstitute for Psychosocial Prevention, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.
Ulrike DingerDepartment of Psychosomatic Medicine and Psychotherapy, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Harald GündelClinic for Psychosomatic Medicine and Psychotherapy, University Hospital Ulm, University of Ulm, Ulm, Germany.
Sabine C HerpertzDepartment of General Psychiatry, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.
Jörg RademacherDepartment of Psychosomatic Medicine and Psychotherapy, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.
Bernhard StraussInstitute for Psychosocial Medicine, Psychotherapy and Psychooncology, University Hospital Jena, Jena, Germany.
Timo StorckDepartment of Clinical Psychology and Psychotherapy, Psychologische Hochschule Berlin, Berlin, Germany.
Ralitsa VassilevaCoordination Centre for Clinical Trials (KKS), Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
Ina BurghausCoordination Centre for Clinical Trials (KKS), Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
Manuel HerbstCoordination Centre for Clinical Trials (KKS), Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
Simiao ChenHeidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.
Christoph NikendeiDepartment for General Internal Medicine and Psychosomatics, University Hospital Heidelberg, University of Heidelberg, Heidelberg, Germany.
Sebastian EulerDepartment of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, Switzerland.
Jana VolkertClinic for Psychosomatic Medicine and Psychotherapy, University Hospital Ulm, University of Ulm, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBorderline Personality Disorder (BPD) is a serious mental disorder. Mentalization-based treatment (MBT) is an evidence-based treatment for individuals with BPD. Specifically, MBT has previously been highlighted for its effectiveness regarding the reduction of suicidal and non-suicidal self-injury (NSSI). Yet, randomized-controlled trials (RCT) on MBT in outpatient settings compared with bona fide treatment (BFT) are still scarce and none has been conducted in Germany. The primary objective of this RCT is to investigate whether outpatient MBT is more effective in the reduction of crisis events (incidences of NSSI and suicide attempts) compared with BFT (namely psychodynamic or cognitive-behavioural psychotherapy) in Germany. Secondary, MBT's efficacy will be investigated with regard to cost-effectiveness within the German health care system, general and interpersonal functioning, BPD and general symptom severity, social adjustment, quality of life, reduction in psychotropic medication and therapy retention. Additionally, moderator as well as common and treatment specific mediator variables will be investigated.

methodsAcross 5 study sites in Germany, 304 individuals of all genders from age 18 to 65 with a BPD diagnosis and NSSI or suicide attempts in the past will be asked to participate in the study for a period of two years. In the first year, patients will receive either MBT or BFT and will take part in continuous scientific assessments. Scientific assessments will continue after therapy completion up to a 12-month follow up. As primary outcome, crisis events will be assessed via ecological momentary assessment (EMA) in one week per month (four weekly assessments) during the first year, and in one week every three months during the second year. Number of crisis events up to 2 years post randomization will be compared between treatment arms using a log-linear regression model following an intention-to-treat approach. Secondary outcomes and mediator variables will be assessed at several timepoints. DISCUSSION: This study investigates efficacy of MBT as BPD specific treatment in an outpatient setting compared with BFT in Germany. Results of this study can address a treatment gap in the German healthcare system, and inform about health economic aspects of BPD treatment as well as mechanisms of psychotherapeutic change.

trial registrationNCT06018272, https://www. CLINICALTRIALS: gov/ , August 30, 2023.

Indexed as

Borderline Personality DisorderCognitive Behavioral TherapyMentalizationPsychotherapy, PsychodynamicAdolescentAdultCost-Benefit AnalysisFemaleGermanyHumansMaleMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicSelf-Injurious BehaviorSuicide, AttemptedBorderline Personality DisorderCrisis eventsEcological Momentary AssessmentHealth economyMechanisms of changeMentalization-based therapyRandomized controlled trial

Identifiers

PMID40217262
PMCPMC11992892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.